EKSO (Ekso Bionics Holdings) Research & Development: $2.63 Mil (TTM As of Mar. 2026)


EKSO Ekso Bionics Holdings Inc EKSO
32 GF Score
Price $11.65
GF Value $4.31
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Ekso Bionics Holdings Research & Development?

Ekso Bionics Holdings EKSO -0.42% 32 Research & Development is $2.63 Mil as of Mar. 2026. GuruFocus rates EKSO with a GF Score™ of 32/100 and a GF Value™ of $4.31 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ekso Bionics Holdings's Research & Development for the three months ended in Mar. 2026 was $0.58 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $2.63 Mil.

Ekso Bionics Holdings  (NAS:EKSO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ekso Bionics Holdings Research & Development Related Terms

Ekso Bionics Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Ekso Bionics Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ekso Bionics Holdings Research & Development Chart

Ekso Bionics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.55 3.63 5.03 3.87 3.03

Ekso Bionics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.99 0.85 0.55 0.64 0.58
EKSO
32GF Score
Ekso Bionics Holdings Inc EKSO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ekso Bionics Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $2.63 Mil mean?
Ekso Bionics Holdings (EKSO) has a Research & Development of $2.63 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Ekso Bionics Holdings and its competitors.
Is Ekso Bionics Holdings' Research & Development too high?
Ekso Bionics Holdings' current Research & Development is $2.63 Mil. Overall, Ekso Bionics Holdings has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ekso Bionics Holdings' Research & Development compare to POCI and HBIO?
Ekso Bionics Holdings' Research & Development of $2.63 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ekso Bionics Holdings and its competitors. Ekso Bionics Holdings's current Research & Development is $2.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ekso Bionics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ekso Bionics Holdings (EKSO) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.31, compared to a current price of $11.65 — trading 170.3% above its estimated fair value. The current Research & Development is $2.63 Mil. Ekso Bionics Holdings' overall GF Score™ is 32/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ekso Bionics Holdings (EKSO), the current Research & Development is $2.63 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ekso Bionics Holdings (EKSO) Overvalued in 2026?

Based on GuruFocus' analysis, Ekso Bionics Holdings stock appears to be overvalued. The current stock price of $11.65 is trading 170.3% above its estimated GF Value™ of $4.31. GuruFocus considers Ekso Bionics Holdings to be Significantly Overvalued.

Key valuation signals for EKSO:

  • Research & Development: $2.63 Mil
  • GF Value™: $4.31 vs. price of $11.65 (170.3% above fair value)
  • GF Score™: 32/100 with 10 warning signs

No single metric tells the full story. See the EKSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ekso Bionics Holdings Business Description

Address 101 Glacier Point, Suite A, San Rafael, CA, USA, 94901
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
32GF Score

Get the complete analysis for EKSO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.65
Price
$4.31
GF Value